INFLAMMATION AND OXIDATIVE STRESS IN EMERGING PSYCHOTIC AND MOOD DISORDERS
Grant number: 1128631 | Funding period: 2017 - 2019
We are conducting four large clinical trials testing anti-inflammatory treatments like ?-3 PUFAs and aspirin in young people who are at high-risk for psychosis or have depression. This proposal adds an important component to this research by investigating inflammatory and oxidative stress markers. We aim to determine if the investigated biomarkers predict the course of illness and response to treatments. The findings will facilitate early intervention and targeted treatment.
Related publications (2)
Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin
Michael Berk, Mohammadreza Mohebbi, Olivia M Dean, Sue M Cotton, Andrew M Chanen, Seetal Dodd, Aswin Ratheesh, G Paul Amminger, Mark Phelan, Amber Weller, Andrew Mackinnon, Francesco Giorlando, Shelley Baird, Lisa Incerti, Rachel E Brodie, Natalie O Ferguson, Simon Rice, Miriam R Schafer, Edward Mullen, Sarah Hetrick
BACKGROUND: Inflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies m..
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial
Christopher G Davey, Andrew M Chanen, Sarah E Hetrick, Sue M Cotton, Aswin Ratheesh, Guenter P Amminger, John Koutsogiannis, Mark Phelan, Edward Mullen, Ben J Harrison, Simon Rice, Alexendra G Parker, Olivia M Dean, Amber Weller, Melissa Kerr, Amelia L Quinn, Lisa Catania, Nikolaos Kazantzis, Patrick D McGarry, Michael Berk
BACKGROUND: Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural..